麻豆传媒

As a ,聽CIHR is committed to advancing open science, research excellence, and greater transparency in clinical trials. To that end, CIHR has introduced new requirements for the registration and public disclosure of the results of clinical trials.

Nominated Principal Investigators receiving CIHR grant funds for clinical trial research on or after January 1, 2022 must comply with the following practices to remain eligible for any new CIHR funding:

• Clinical trials must be registered in a publicly available, free-to-access, searchable clinical trial registry complying with the before the researcher meets with the first study participant.
• [NEW] Public disclosure of results must be done within a mandated time frame
• [NEW] All study publications must include the registration number/Trial ID (to be specified in the article summary/abstract).聽
• Publications describing clinical trial results must be open access from the date of publication.
• Summary results must be publicly available within 12 months from the last visit of the last participant (for collection of data on the primary outcome).

For more information, you are invited to consult:

By aligning with international best practices for clinical trial reporting, CIHR is proud to demonstrate its ongoing commitment to advance open science and research excellence. Timely disclosure of results reduces waste in research, increases value and efficiency in the use of funds and reduces reporting bias, which should lead to better decision making in health policy and practice.

CIHR is available to assist with interpretation of the new requirements. If you have questions, please contact the .